NYSEAM:YMI - Post by User
Post by
insiderinfocanon Nov 08, 2009 6:43pm
446 Views
Post# 16465639
Merriman Initiates Coverage Buy Target 5.50-6.50
Merriman Initiates Coverage Buy Target 5.50-6.50Merriman Curhan Ford Initiates Coverage on YM BioSciences (YMI) with a Buy; Intriguing Opportunity
November 5, 2009 7:51 AM EST
Merriman Curhan Ford initiates coverage on YM BioSciences, Inc. (NYSE Amex: YMI) with a Buy. Valuation range $5.50-6.50.
Merriman analyst says, "We believe YM offers up an intriguing opportunity for investors including
growing revenue from nimotuzumab, a marketed product, significant market expansion potential for nimotuzumab and upside potential for pipeline products. After hitting previous hurdles on both the
data and perception fronts, YM has come a long way and we believe is poised to garner significant market share in the oncology market targeting EGFR due to nimotuzumab’s differentiated profile. We recommend that investors own YM BioSciences based on a definitive product opportunity and a compelling valuation."
To see more analyst ratings on YMI Click Here.
YM Biosciences Inc., a biopharmaceutical company, engages in the licensing and commercialization of drug products and technologies primarily for the treatment of cancer or cancer-related conditions worldwide.